Icon PLC
ICLR
ISIN IE0005711209 / Valor 1017575
Icon PLC
UMushroom community rating:
About company
ICON plc is a leading global provider of outsourced drug and medical device development and commercialization services, catering to pharmaceutical, biotechnology, and medical device companies as well as government and public health organizations. The company specializes in managing the entire product lifecycle, including the planning, execution, and analysis of Phase I-IV clinical trials, which range from small single-site studies to large, multinational projects and advancements in cell and gene therapy. ICON also offers Functional Service Provision (FSP), delivering essential support services in areas such as finance, IT, human resources, sales, quality assurance, facilities, administration, legal, and procurement. With over 13,000 employees and more than 90 global partnerships, ICON integrates its Strategic Solutions teams within clients' operations to enhance efficiency and accelerate the market entry of new therapeutics and devices. Additionally, ICON is committed to developing talent through various early career programs, fostering a culture of continuous learning and professional growth.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (21.09.2025):
Icon PLC reported its financial results for the second quarter of 2025, demonstrating strong business performance with significant increases in gross business wins and net income. Despite minor revenue growth and ongoing economic challenges, the company has updated its full-year guidance, reflecting confidence in continued growth and strategic financial management.
Strong Business Wins
Gross business wins for Q2 2025 reached $2,966 million, marking a 10.6% increase from Q1 2025. Net business wins stood at $2,057 million with a book-to-bill ratio of 1.02, indicating robust demand and effective sales performance.
Revenue and Profit Growth
Quarter two revenue was $2,017.4 million, showing a slight increase of 0.8% compared to Q1 2025. GAAP net income rose by 30.7% year-over-year to $183.0 million, translating to $2.30 per diluted share.
Adjusted Earnings
Adjusted EBITDA for Q2 2025 was $396.0 million, accounting for 19.6% of revenue. Adjusted net income reached $259.5 million, or $3.26 per diluted share, reflecting the company's focus on operational efficiency.
Share Repurchase and Financial Position
Icon PLC repurchased $250.0 million of its stock in Q2 at an average price of $146 per share. The Board authorized an expansion of the share repurchase program by an additional $500 million, bringing the total authorized repurchases to $1 billion.
Updated Financial Guidance
The company has amended its full-year 2025 revenue guidance to a range of $7,850 - $8,150 million, up by $50 million at the midpoint. Additionally, full-year adjusted diluted earnings per share guidance has been updated to $13.00 - $14.00.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
14393 M
Market cap (USD)
777,993
Daily traded volume (Shares)
211.185 / 207.1
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
